Clinical Trial Update: A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia [Phase 3]

View source ↗

Summary

This document reports the completion of a prospective open-label extension study of gaboxadol in primary insomnia (Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• Gaboxadol (gaboxadol)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Primary Insomnia | Phase 3 | Status: COMPLETED